Mixed-Phenotype Acute Leukemia Transforming Into Acute Myelomonocytic Leukemia (AML M4): A Case Report and Therapeutic Challenges

Mixed-phenotype acute leukemia (MPAL) accounts for a fraction of de novo acute leukemias and carries a dismal prognosis, especially when adverse lesions such as monosomy 7 are present. Consensus on optimal frontline therapy remains lacking. Herein, we present a 69-year-old woman who presented with pancytopenia and 79% circulating blasts. Immunophenotyping and cytogenetics established T/myeloid MPAL with a hypodiploid clone 45, XX, dic(7;12)(p11.2;p13)(19)/46,XX and an <i>IDH2</i> R140Q mutation. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD) induction achieved morphological complete remission, but measurable residual disease (MRD) persisted. Consolidation with mini-cyclophosphamide, vincristine, and dexamethasone (mini-CVD) and prednisone, vincristine, methotrexate, and 6-mercaptopurine (POMP) maintenance failed to eradicate MRD, and overt relapse occurred at month 7. Nelarabine salvage was initiated. After two nelarabine cycles (month 8.5), bone marrow contained 85% myelomonocytic blasts. Cytogenetic evolution to 45,XX,psu dic(7;12)(p11.2;p11.2)/45,idem,del(16)(q12) marked transformation to acute myelomonocytic leukemia (AML-M4). Profound pancytopenia led to invasive pulmonary aspergillosis and symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. With refractory disease and escalating infectious morbidity, active therapy was discontinued; the patient died 11 months after diagnosis. This case illustrates rapid clonal evolution of T/myeloid MPAL into chemoresistant AML-M4 driven by persistent chromosome-7 loss and acquisition of del(16q). Early molecular risk stratification and deployment of targeted agents, venetoclax-based combinations, or timely allogeneic transplantation should be considered before irreversible genomic complexity emerges. Prospective studies tailored to high-risk cytogenetic subsets of MPAL are urgently needed.

Authors

Institutions

Publication Details

Journal
Cureus
Published
2025-11-11
DOI
https://doi.org/10.7759/cureus.96576
Primary Topic
Acute Myeloid Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Mixed-Phenotype Acute Leukemia Transforming Into Acute Myelomonocytic Leukemia (AML M4): A Case Report and Therapeutic Challenges

Rodney B. Brink, Raja Gummalla, Xiaowei Malone, Bakr Alhayek et al.
Cureus
Acute Myeloid Leukemia Research
article

Mixed-Phenotype Acute Leukemia Transforming Into Acute Myelomonocytic Leukemia (AML M4): A Case Report and Therapeutic Challenges

Rodney B. Brink, Raja Gummalla, Xiaowei Malone, Bakr Alhayek, Tamim Rabie
article en

Abstract

Mixed-phenotype acute leukemia (MPAL) accounts for a fraction of de novo acute leukemias and carries a dismal prognosis, especially when adverse lesions such as monosomy 7 are present. Consensus on optimal frontline therapy remains lacking. Herein, we present a 69-year-old woman who presented with pancytopenia and 79% circulating blasts. Immunophenotyping and cytogenetics established T/myeloid MPAL with a hypodiploid clone 45, XX, dic(7;12)(p11.2;p13)(19)/46,XX and an <i>IDH2</i> R140Q mutation. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD) induction achieved morphological complete remission, but measurable residual disease (MRD) persisted. Consolidation with mini-cyclophosphamide, vincristine, and dexamethasone (mini-CVD) and prednisone, vincristine, methotrexate, and 6-mercaptopurine (POMP) maintenance failed to eradicate MRD, and overt relapse occurred at month 7. Nelarabine salvage was initiated. After two nelarabine cycles (month 8.5), bone marrow contained 85% myelomonocytic blasts. Cytogenetic evolution to 45,XX,psu dic(7;12)(p11.2;p11.2)/45,idem,del(16)(q12) marked transformation to acute myelomonocytic leukemia (AML-M4). Profound pancytopenia led to invasive pulmonary aspergillosis and symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. With refractory disease and escalating infectious morbidity, active therapy was discontinued; the patient died 11 months after diagnosis. This case illustrates rapid clonal evolution of T/myeloid MPAL into chemoresistant AML-M4 driven by persistent chromosome-7 loss and acquisition of del(16q). Early molecular risk stratification and deployment of targeted agents, venetoclax-based combinations, or timely allogeneic transplantation should be considered before irreversible genomic complexity emerges. Prospective studies tailored to high-risk cytogenetic subsets of MPAL are urgently needed.

CureusVol. 17(11)
AdventHealth Tampa (US), Maria Hilf Krankenhaus (DE)
Openalex Percentile: Top 56%
Acute Myeloid Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.